Osteoporosis

Dec 2017
Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide.
Calcif Tissue Int. 2017 Dec 28 [online ahead of print]. McClung MR, Williams GC, Hattersley G, Fitzpatrick LA, Wang Y, Miller PD.

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Osteoporos Int. 2017 Dec 19 [online ahead of print]. Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G.

Nov 2017
Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
Osteoporos Int. 2017 Nov 22 [online ahead of print]. Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.

August 2017
The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.
J Bone Miner Res. 2017;32:1625-1631. McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA.

June 2017
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Regul Toxicol Pharmacol. 2017;86:356-365. Jolette J, Attalla B, Varela A, Long GG, Mellal N, Trimm S, Smith SY, Ominsky MS, Hattersley G.

April 2017
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial.
Bone. 2017;97:314-319. Moreira C, Fitzpatrick LA, Wang Y, Recker RR.

February 2017
Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial.

Mayo Clin Proc. 2017;92:200-210. Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.

One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.
Bone. 2017;95:143-150. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G.

January 2017
One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption.
J Bone Miner Res. 2017;32:24-33. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G.

Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors.
J Bone Miner Res. 2017;32:17-23. Cosman F, Hattersley G, Hu MY, Williams GC, Fitzpatrick LA, Black DM.

November 2016
Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats.
Calcif Tissue Int. 2016;99:489-499. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G.

August 2016
Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial.

JAMA. 2016;316:722-733. Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators.

January 2016
Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling.
Endocrinology. 2016;157:141-149. Hattersley G, Dean T, Corbin BA, Bahar H, Gardella TJ.

February 2015
Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2015;100:697-706. Leder BZ, O’Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.

Oncology

May 2017
Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti-tumor activity in multiple ER+ breast cancer patient-derived xenograft models.
Clin Cancer Res. 2017;23:4793-4804. Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown J, Purandare DM, Hattersley G, Garner F.

October 2015
RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models.
Anticancer Drugs. 2015;26(9):948-56. Garner F, Shomali M, Paquin D, Lyttle CR, Hattersley G.